Advances in serological non-invasive diagnosis for metabolic dysfunction-associated fatty liver disease
10.3760/cma.j.cn501113-20230831-00085
- VernacularTitle:代谢相关脂肪性肝病无创血清学诊断的研究进展
- Author:
Jinhan ZHAO
1
;
Jing ZHANG
Author Information
1. 首都医科大学附属北京佑安医院肝病中心三科，北京 100069
- Keywords:
Metabolic associated fatty liver disease;
Metabolic-associated steatohepatitis;
Liver fibrosis;
Serological markers
- From:
Chinese Journal of Hepatology
2023;31(12):1235-1239
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic dysfunction-associated fatty liver disease is a chronic liver condition associated with metabolic abnormalities characterized by hepatic steatosis that can progress to metabolic-related steatohepatitis, liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Currently, a liver biopsy is still the gold standard for diagnosis but due to its invasiveness and risk of complications, the development of serological diagnostic indicators to achieve non-invasive diagnosis has been a hot research topic in recent years. Herein, well-researched serological non-invasive diagnostic indicators present now for fatty livers are reviewed.
